Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Most schools keep epinephrine on hand, yet still require allergic students to bring their own autoinjectors — creating costly overlap. A national survey of school nurses found that while stock epinephrine significantly reduces emergencies where the drug is unavailable, nearly three-quarters of nurses still prefer a dual-coverage model. Newer delivery formats like nasal sprays could ease hesitancy and cut waste.
Most U.S. schools now stock epinephrine for anaphylactic emergencies — but that hasn't stopped them from also requiring students with severe allergies to carry their own. A national survey of 349 school nurses, presented at the ACAAI Annual Scientific Meeting, found that 87.3% of schools kept stock epinephrine on site, yet 71.3% of those schools still mandated personal autoinjectors from students. The result? A significant — and costly — overlap in supply, with high rates of unused, expiring devices.
Despite the redundancy, stock epinephrine clearly matters. Schools without it were 4.42 times more likely to face an emergency where epinephrine wasn't available (P <0.001). Still, 73.6% of nurses favored keeping both stock and personal supply, showing reluctance to shift to a stock-only model that researchers say could reduce financial burdens on families and administrative strain on schools.
Newer epinephrine formats — including an approved nasal spray (neffy), a sublingual film, and a nasal dry powder — may help address hesitancy around administration and offer longer shelf lives (up to 2 years vs. ~1 year for autoinjectors), making stock programs more practical.
By the Numbers:
Why it matters: With food allergies affecting ~8% of children, ensuring reliable epinephrine access in schools is a critical safety issue. This data highlights a gap between policy intent and real-world practice — and points to newer delivery formats as a potential path toward simpler, more cost-effective anaphylaxis preparedness.